

Ref: FOIA Reference 2019/20-109

Royal Stoke University Hospital

Quality, Safety and Compliance Department Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Date: 6th June 2019

Email foi@uhnm.nhs.uk

Dear

I am writing in response to your email dated 28th May 2019 requesting information under the Freedom of Information Act (2000) regarding Biologics and Biosimilar prescribing.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I wonder if you can help with regards to a Freedom of Information request I have for Biologics and Biosimilar prescribing. Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:

Treatment	Total	Rheumatology	Dermatology	Gastroenterology
Abatacept				
(Orencia)				
Adalimumab				
biosimilar				
(Amgevita)				
Adalimumab				
biosimilar				
(Hulio)				
Adalimumab				
(Humira)				
Adalimumab				
biosimilar				
(Hyrimoz)				
Adalimumab				
bioisimilar				
(Imraldi)				
Apremilast				
(Otezla)				
Baricitinib				
(Olumiant)				
Brodalumab				
(Kyntheum)				
Certolizumab				
(Cimzia)				
Dimethyl				







Fumarate		
(Skilarence)		
Etanercept		
(Enbrel)		
Etanercept		
Biosimilar		
(Benepali)		
Etanercept		
Biosimilar		
(Erelzi)		
Golimuab		
(Simponi)		
Guselkumab		
(Tremfya)		
Infliximab		
(Flixabi)		
Infliximab		
(Inflectra)		
Infliximab		
(Remicade)		
Infliximab		
(Remsima)		
Ixekizumab		
(Taltz)		
Rituximab		
(Mabthera)		
Rituximab		
Biosimilar		
(Rixathon)		
Rituximab		
Biosimilar		
(Truxima)		
Sarilumab		
(Kevzara)		
Secukinumab		
(Cosentyx)		
Tildrakizumab		
(llumetri)		
Tocilizumab (Ro		
Actemra)		
Tofacitinib		
(Xeljanz)		
Ustekinumab		
(Stelara)		
Vedolizumab		
(Entyvio)		

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:







Treatment	Total	Rheumatology	Dermatology	Gastroenterology
Abatacept	0	Not applicable	0	0
(Orencia)				
Adalimumab	0	Not applicable	0	0
biosimilar				
(Amgevita)				
Adalimumab	0	Not applicable	0	0
biosimilar (Hulio)				
Adalimumab	339	Not applicable	63	276
(Humira)				
Adalimumab	24	Not applicable	15	9
biosimilar				
(Hyrimoz)				
Adalimumab	0	Not applicable	0	0
bioisimilar				
(Imraldi)				
Apremilast	29	Not applicable	29	0
(Ótezla)				
Baricitinib	0	Not applicable	0	0
(Olumiant)				
Brodalumab	0	Not applicable	0	0
(Kyntheum)				
Certolizumab	0	Not applicable	0	0
(Cimzia)				
Dimethyl	Less than 5	Not applicable	Less than 5	0
Fumarate				
(Skilarence)				
Etanercept	Less than 5	Not applicable	Less than 5	0
(Enbrel)				
Etanercept	0	Not applicable	0	0
Biosimilar				
(Benepali)				
Etanercept	Less than 5	Not applicable	Less than 5	0
Biosimilar (Erelzi)				
Golimuab	Less than 5	Not applicable	0	Less than 5
(Simponi)				
Guselkumab	0	Not applicable	0	0
(Tremfya)				
Infliximab	0	Not applicable	0	0
(Flixabi)				
Infliximab	100	Not applicable	0	100
(Inflectra)				
Infliximab	19	Not applicable	0	19
(Remicade)				
Infliximab	0	Not applicable	0	0
(Remsima)				
Ixekizumab	Less than 5	Not applicable	Less than 5	0
(Taltz)				
Rituximab	0	Not applicable	0	0
(Mabthera)				
Rituximab	0	Not applicable	0	0
Biosimilar				
(Rixathon)				
· · · · · · · · · · · · · · · · · · ·				

:







Rituximab Biosimilar (Truxima)	0	Not applicable	0	0
Sarilumab (Kevzara)	0	Not applicable	0	0
Secukinumab (Cosentyx)	42	Not applicable	42	0
Tildrakizumab (Ilumetri)	0	Not applicable	0	0
Tocilizumab (Ro Actemra)	0	Not applicable	0	0
Tofacitinib (Xeljanz)	0	Not applicable	0	0
Ustekinumab (Stelara)	87	Not applicable	50	37
Vedolizumab (Entyvio)	46	Not applicable	0	46

Please note: UHNM does not treat rheumatology patients. This refers to 2018/19 data. We have excluded the paediatric specialty. A limitation to the accuracy of the data is due to any incorrect booking out on the computer system due to lack of information on the prescription.

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <u>http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</u>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.







The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via <u>www.ico.org.uk</u>.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,

(ehrer

Jean Lehnert Information Governance Manager



